Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Dyslipidemia is a critical risk factor for cardiovascular diseases
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Subscribe To Our Newsletter & Stay Updated